Cosponsor
No direct connectionCosponsorship · Reviewed automated analysis
Compared with: Support for Medicare for All and increased access to mental health care.
The stated policy goal is support for Medicare for All and increased access to mental health care. The cosponsored bill is the PLASMA Act, which only phases in price adjustments for certain plasma-derived products under the Medicare prescription drug benefit. That is a targeted drug-pricing change within Medicare, not a direct advance of Medicare for All, and the passages provided do not mention mental health care access. Because the action is narrower and does not directly address the specific policy goal, a defensible scored comparison cannot be made.
“He is proud to support Medicare for All and is a champion for increased access to mental health care.”
Official statement · Captured 2026-10-28
Supporting provisions
“Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.”
“The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
Partly supportsCosponsorship · Reviewed automated analysis
Compared with: Addressing systemic disparities that affect health care access.
The cosponsored bill would reduce Medicare discount requirements for plasma-derived products for several years before gradually returning to the standard discount levels. That could modestly improve access for patients who rely on these specialty medicines, but the described mechanism is a pricing transition under Medicare rather than a direct policy targeting systemic health care disparities, so the support is narrower and indirect relative to the stated goal.
“In the Senate, Alex has prioritized addressing the systemic disparities that affect health care access.”
Official statement · Captured 2026-10-28
Supporting provisions
“Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.”
“The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.”
Opposing provisions
“Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
MixedCosponsorship · Reviewed automated analysis
Compared with: Guaranteeing quality, affordable, and equitable health care for every American.
The cosponsored bill narrows and phases in Medicare prescription drug discount requirements for plasma-derived products rather than directly advancing the stated goal of guaranteeing affordable, equitable health care for every American. It could lower costs for some patients who use these specialty medicines, but the available summary is limited to a specific drug category and a phased discount adjustment, so it is not a direct or broad-based advancement of universal affordable and equitable care.
“Alex is working to guarantee quality, affordable, and equitable health care for every American.”
Official statement · Captured 2026-10-28
Supporting provisions
“The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.”
“Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.”
Opposing provisions
“Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
“Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.”Official summary source